3-HO-PCP Stats & Data
Oc1cccc(c1)C1(CCCCC1)N1CCCCC1AMSXTZUCNOKUEN-UHFFFAOYSA-NReceptor Profile
Receptor Actions
Receptor Binding
History & Culture
3-HO-PCP was first synthesized in 1978 during investigations into the structure-activity relationships of phencyclidine (PCP) derivatives. Throughout the 1980s, researchers continued to characterize its pharmacological properties, discovering its activity at opioid receptors in animal models during this period. The compound remained largely unknown outside academic circles until 1999, when a chemist operating under the pseudonym "John Q. Beagle" discussed it in a post on The Hive, a now-defunct online chemistry forum. Beagle highlighted the compound's substantially increased potency compared to PCP and its notable affinity for opioid receptors. Even before the substance became commercially available, members of the Bluelight forum had begun documenting its psychoactive effects based on personal experimentation. Around 2009, 3-HO-PCP entered the research chemical market through online vendors. Despite being structurally related to PCP—a compound that had developed considerable notoriety through decades of media coverage and street names like "angel dust," "rocket fuel," and "sherm"—3-HO-PCP has remained one of the more obscure members of the arylcyclohexylamine class. It continues to be distributed primarily through gray-market online sources, with very little formal research having been conducted on its effects, metabolism, or toxicity in humans.
Effect Profile
Curated + 22 ReportsStrong dissociative depth, motor impairment, and mania with moderate insight
Duration Timeline
BluelightCommunity Effects
TripSitTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Tolerance builds rapidly with repeated use over days and decays over 1–2+ weeks; numbers are approximate and largely anecdotal for this specific analogue.
Cross-Tolerances
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
Erowid + BluelightEffects aggregated from 22 experience reports (17 Erowid + 5 Bluelight)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 20
Adverse Effects 24
Real-World Dose Distribution
62K DosesFrom 160 individual dose entries
Oral (n=71)
Rectal (n=69)
Topical (n=5)
Insufflated (n=11)
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Redose Patterns
Redosing behavior across 13 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Czech Republic | Schedule I (List 4) | Controlled under Nařízení vlády č. 463/2013 Sb. (§ 1, d), 1.). Permitted for research purposes and restricted therapeutic applications only. |
| Germany | Unscheduled | Not listed as a controlled substance under the Betäubungsmittelgesetz (BtMG). However, under §2 of the Arzneimittelgesetz (AMG), sale for human consumption remains prohibited. |
| Sweden | Illegal | Prohibited substance under Swedish drug control legislation. |
| Switzerland | Controlled (Verzeichnis E) | Specifically named as a controlled substance in Verzeichnis E of Swiss narcotics legislation. |
| Turkey | Illegal | Classified as a controlled drug under Turkish law. Possession, production, supply, and importation are prohibited. |
| United Kingdom | Class B | Controlled under the Misuse of Drugs Act 1971 via the arylcyclohexylamine generic clause introduced by S.I. 2013/239, effective February 26, 2013. As a derivative of 1-phenylcyclohexylamine with a 1-piperidyl group and hydroxy substitution on the phenyl ring, it falls within this catch-all provision. Possession, production, supply, and importation are criminal offenses. |
Harm Reduction
drugs.wikiPotency is high and interindividual variability is large; 1–2 mg can noticeably change effects, so weigh with a calibrated 0.001 g scale or volumetrically. Onset—especially intranasal—can be delayed 40–90+ minutes; redosing during the come‑up is a common trigger for blackouts and hazardous behavior. Several experienced users and moderators note unusually prominent muscle tension/soreness after higher doses; spacing sessions reduces cumulative strain. Intranasal use is often caustic and can inflame sinuses; oral routes are gentler on mucosa. Mislabeling/adulteration has been documented in the wild (e.g., MD‑PiHP sold as 3‑HO‑PCP); use professional drug checking when possible, and do not assume reagent tests can definitively identify PCP analogues. The compound’s opioid receptor profile in vitro is debated; regardless, mixing with CNS depressants increases sedation and slows breathing—avoid these combinations. Dissociatives in general can aggravate mood instability, mania, and psychosis; people with a history of these should avoid or use only with strong support and conservative dosing in a safe setting. Heavy, frequent dissociative use (well‑established for ketamine) is linked to urinary tract problems; while specific data for 3‑HO‑PCP are limited, adopt the same precautions—hydrate, avoid daily use, and stop if urinary symptoms appear. Because ambulation can be preserved while judgment is impaired, trips should be done sitting/lying down with a sober sitter available to prevent accidents.
References
Data Sources
Cited References
- Bluelight: The Big & Dandy 3-HO-PCP Thread
- CAHMA: Safer Using - 3-HO-PCP
- Drug Users Bible: 3-HO-PCP
- Erowid: 3-HO-PCP Experience Reports
- Itzhak et al. (1981) - On the opioid nature of phencyclidine and its 3-hydroxy derivative
- Kalir et al. (1978) - Structure-activity relationship of some phencyclidine derivatives
- Morris & Wallach (2014) - From PCP to MXE: A comprehensive review of dissociative drugs
- PMC: Severe Toxicity to 3-Hydroxyphencyclidine and N-Ethylhexedrone Case Report
- Substance Search: 3-HO-PCP
- WHO Critical Review: 3-Hydroxyphencyclidine
- TripSit Factsheet: 3-HO-PCP
Drugs.wiki References
- Hi‑Ground harm‑reduction brief: Arylcyclohexylamines (includes 3‑HO‑PCP dose ranges)
- SubstanceSearch: 3‑HO‑PCP overview (onset/duration summary; rarity; negative side‑effects)
- Bluelight Big & Dandy 3‑HO‑PCP thread (muscle tension; seizure concern; caution consensus)
- EffectIndex trip reports for 3‑HO‑PCP (oral 15 mg; and 10 mg intranasal)
- Erowid: 3‑MeO‑PCP effects/duration (ACH intranasal irritation; dissociative risks used for class‑level cautions)
- TripSit PCP factsheet (general ACH cautions: CNS depression with depressants; mobility risk)
- Reddit reagent‑testing/adulteration report: product sold as 3‑HO‑PCP was MD‑PiHP
- DrugWise: Ketamine risks (urinary tract harm; extrapolated caution to ACHs)